241 related articles for article (PubMed ID: 32615707)
1. Amino Acid Transporters as Potential Therapeutic Targets in Thyroid Cancer.
Enomoto K; Hotomi M
Endocrinol Metab (Seoul); 2020 Jun; 35(2):227-236. PubMed ID: 32615707
[TBL] [Abstract][Full Text] [Related]
2. LncRNAs as Potential Therapeutic Targets in Thyroid Cancer.
Javed Z; Ahmed Shah F; Rajabi S; Raza Q; Iqbal Z; Ullah M; Ahmad T; Salehi B; Sharifi-Rad M; Pezzani R; Yaqoob F; Sadia H; Iriti M; Sharifi-Rad J; Cho WC
Asian Pac J Cancer Prev; 2020 Feb; 21(2):281-287. PubMed ID: 32102500
[TBL] [Abstract][Full Text] [Related]
3. Amino Acid transporters in cancer and their relevance to "glutamine addiction": novel targets for the design of a new class of anticancer drugs.
Bhutia YD; Babu E; Ramachandran S; Ganapathy V
Cancer Res; 2015 May; 75(9):1782-8. PubMed ID: 25855379
[TBL] [Abstract][Full Text] [Related]
4. New approaches to thyroid cancer.
Cohen EE
Clin Adv Hematol Oncol; 2012 Apr; 10(4):255-6. PubMed ID: 22706487
[No Abstract] [Full Text] [Related]
5. RAS proto-oncogene in medullary thyroid carcinoma.
Moura MM; Cavaco BM; Leite V
Endocr Relat Cancer; 2015 Oct; 22(5):R235-52. PubMed ID: 26285815
[TBL] [Abstract][Full Text] [Related]
6. Oncology Therapeutics Targeting the Metabolism of Amino Acids.
Muhammad N; Lee HM; Kim J
Cells; 2020 Aug; 9(8):. PubMed ID: 32824193
[TBL] [Abstract][Full Text] [Related]
7. The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer.
De Falco V; Carlomagno F; Li HY; Santoro M
Best Pract Res Clin Endocrinol Metab; 2017 Jun; 31(3):307-318. PubMed ID: 28911727
[TBL] [Abstract][Full Text] [Related]
8. Regulators of the RAS-ERK pathway as therapeutic targets in thyroid cancer.
Zaballos MA; Acuña-Ruiz A; Morante M; Crespo P; Santisteban P
Endocr Relat Cancer; 2019 Jun; 26(6):R319-R344. PubMed ID: 30978703
[TBL] [Abstract][Full Text] [Related]
9. [New therapies in thyroid cancer].
López Mondéjar P; Galofré JC
Med Clin (Barc); 2016 Apr; 146(7):324-9. PubMed ID: 26723936
[No Abstract] [Full Text] [Related]
10. A novel therapeutic approach for anaplastic thyroid cancer through inhibition of LAT1.
Enomoto K; Sato F; Tamagawa S; Gunduz M; Onoda N; Uchino S; Muragaki Y; Hotomi M
Sci Rep; 2019 Oct; 9(1):14616. PubMed ID: 31601917
[TBL] [Abstract][Full Text] [Related]
11. Epigenetics in Medullary Thyroid Cancer: From Pathogenesis to Targeted Therapy.
Vitale G; Dicitore A; Messina E; Sciammarella C; Faggiano A; Colao A
Recent Pat Anticancer Drug Discov; 2016; 11(3):275-82. PubMed ID: 27306881
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapy for thyroid cancer: An updated review of investigational agents.
Deshpande HA; Gettinger SN; Sosa JA
Curr Opin Investig Drugs; 2010 Jun; 11(6):661-8. PubMed ID: 20496261
[TBL] [Abstract][Full Text] [Related]
13. Targeted agents for advanced thyroid cancer: "knowledge is power" - the role of multikinase inhibitors.
Mangano A; Kim HY; Lianos GD; Roukos DH; Dionigi G
Future Oncol; 2014 Nov; 10(14):2099-102. PubMed ID: 25471022
[No Abstract] [Full Text] [Related]
14. Heat shock proteins in thyroid malignancies: Potential therapeutic targets for poorly-differentiated and anaplastic tumours?
Lettini G; Pietrafesa M; Lepore S; Maddalena F; Crispo F; Sgambato A; Esposito F; Landriscina M
Mol Cell Endocrinol; 2020 Feb; 502():110676. PubMed ID: 31812782
[TBL] [Abstract][Full Text] [Related]
15. Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.
Lopez JP; Wang-Rodriguez J; Chang C; Chen JS; Pardo FS; Aguilera J; Ongkeko WM
Arch Otolaryngol Head Neck Surg; 2007 Oct; 133(10):1022-7. PubMed ID: 17938326
[TBL] [Abstract][Full Text] [Related]
16. Amino acid transporters as emerging therapeutic targets in cancer.
Saito Y; Soga T
Cancer Sci; 2021 Aug; 112(8):2958-2965. PubMed ID: 34091991
[TBL] [Abstract][Full Text] [Related]
17. Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis.
Sadowski SM; Boufraqech M; Zhang L; Mehta A; Kapur P; Zhang Y; Li Z; Shen M; Kebebew E
Oncotarget; 2015 Jul; 6(20):18038-49. PubMed ID: 25945839
[TBL] [Abstract][Full Text] [Related]
18. Emerging strategies for managing differentiated thyroid cancers refractory to radioiodine.
Bulotta S; Celano M; Costante G; Russo D
Endocrine; 2016 May; 52(2):214-21. PubMed ID: 26690657
[TBL] [Abstract][Full Text] [Related]
19. Targeted Therapy in Thyroid Cancer: State of the Art.
Valerio L; Pieruzzi L; Giani C; Agate L; Bottici V; Lorusso L; Cappagli V; Puleo L; Matrone A; Viola D; Romei C; Ciampi R; Molinaro E; Elisei R
Clin Oncol (R Coll Radiol); 2017 May; 29(5):316-324. PubMed ID: 28318881
[TBL] [Abstract][Full Text] [Related]
20. Update on thyroid cancer treatment.
Regalbuto C; Frasca F; Pellegriti G; Malandrino P; Marturano I; Di Carlo I; Pezzino V
Future Oncol; 2012 Oct; 8(10):1331-48. PubMed ID: 23130931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
